<DOC>
	<DOCNO>NCT00030537</DOCNO>
	<brief_summary>RATIONALE : Biological therapy erlotinib may interfere growth tumor cell slow growth tumor . PURPOSE : Phase II trial study effectiveness erlotinib treat patient locally advance metastatic breast cancer .</brief_summary>
	<brief_title>Erlotinib Treating Patients With Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether change epidermal growth factor receptor ( EGFR ) phosphorylation detect tumor patient locally advance metastatic breast cancer treat erlotinib . - Determine whether change parameter signal transduction downstream EGFR ( ERK AKT ) detect tumor patient treated drug . - Determine toxicity drug patient . - Determine response duration time progression patient treat drug . - Correlate EGFR phosphorylation level clinical finding time progression patient treat drug . - Correlate pharmacokinetics drug change EGFR phosphorylation tumor biopsy patient . OUTLINE : Patients receive oral erlotinib daily . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Patients follow within 4 week . PROJECTED ACCRUAL : A total 15-20 patient accrue study within 7-10 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma breast Locally advance metastatic disease Incurable disease Tumor accessible biopsy Prior breast cancer allow No symptomatic untreated brain metastasis carcinomatous meningitis Neurologically stable patient inactive brain metastasis allow corticosteroid least 4 week prior study Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Male female Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin normal ALT/AST great 2.5 time upper limit normal Renal : Creatinine normal OR Creatinine clearance least 60 mL/min Cardiovascular : LVEF least 40 % No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Ophthalmic : No prior abnormality cornea , include : Dry eye syndrome Sjogren 's syndrome Congenital abnormality ( e.g. , Fuch 's dystrophy ) Abnormal slitlamp examination vital dye ( e.g. , fluorescein BengalRose ) Abnormal corneal sensitivity test ( e.g. , Schirmer test similar tear production test ) No concurrent use contact lenses Other : No prior allergic reaction attribute compound similar chemical biologic composition erlotinib ( e.g. , gefitinib anilinoquinazolines ) No concurrent uncontrolled illness No active infection No uncontrolled diabetes mellitus No psychiatric illness social situation would preclude study No untreated lifethreatening disease No primary malignancy within past 5 year except carcinoma situ cervix nonmelanoma skin cancer Weight le 136 kg Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) No concurrent chemotherapy Endocrine therapy : See Disease Characteristics At least 2 week since prior hormonal therapy No concurrent hormonal therapy Radiotherapy : At least 3 week since prior radiotherapy No concurrent radiotherapy except localized external beam radiotherapy palliative treatment metastatic disease ( include significant cardiac muscle within radiotherapy field ) Surgery : Not specify Other : No concurrent investigational anticancer agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2002</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>